NOVOB N Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 2,643.43 |
| 52 Week High | DKK 2,708.33 |
| 52 Week Low | DKK 1,679.60 |
| Beta | 0.15 |
| 11 Month Change | 4.72% |
| 3 Month Change | -0.66% |
| 1 Year Change | 56.68% |
| 33 Year Change | 158.47% |
| 5 Year Change | n/a |
| Change since IPO | 163.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVOB N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -0.3% |
| 1Y | 56.7% | -14.2% | 1.4% |
Return vs Industry: NOVOB N exceeded the MX Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: NOVOB N exceeded the MX Market which returned 1.4% over the past year.
Price Volatility
| NOVOB N volatility | |
|---|---|
| NOVOB N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 5.7% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: NOVOB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOVOB N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 69,260 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVOB N fundamental statistics | |
|---|---|
| Market cap | Mex$10.94t |
| Earnings (TTM) | Mex$261.03b |
| Revenue (TTM) | Mex$749.15b |
41.9x
P/E Ratio14.6x
P/S RatioIs NOVOB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVOB N income statement (TTM) | |
|---|---|
| Revenue | DKK 258.00b |
| Cost of Revenue | DKK 39.92b |
| Gross Profit | DKK 218.09b |
| Other Expenses | DKK 128.19b |
| Earnings | DKK 89.90b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | 20.28 |
| Gross Margin | 84.53% |
| Net Profit Margin | 34.84% |
| Debt/Equity Ratio | 50.7% |
How did NOVOB N perform over the long term?
See historical performance and comparison